����������

The Food and Drug Administration will accept  through Dec. 11 for experts to serve on a committee that will advise the agency on issues related to digital health technologies, from artificial intelligence/machine learning and digital therapeutics to wearables and remote patient monitoring. 
 
“Many of these technologies are novel and tend to rapidly change; it’s our duty to seek as much knowledge on them as possible as we determine and implement appropriate regulation to encourage innovation while protecting public health,” Troy Tazbaz, director of the FDA’s Digital Health Center of Excellence.